{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:28:33Z","timestamp":1760149713251,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Influenza is a major cause of morbidity and mortality. The protective effect of a trivalent influenza vaccine (TIV) is undetermined in military personnel. We conducted an open-label, cluster randomized trial on active-duty servicemen of Beijing, Tianjin, and Shijiazhuang, who were randomly assigned to receive either a single dose of TIV or no treatment, according to cluster randomized sampling. The subjects were then followed for a maximum of six months to assess the incidence of laboratory-confirmed influenza. A total of 5445 subjects in 114 clusters received one dose of TIV before the 2015\/2016 influenza season. Laboratory-confirmed influenza was identified in 18 in the vaccine group compared with 87 in the control group (6031 subjects in 114 clusters), resulting in a vaccine effectiveness (VE) of 76.4% (95%CI: 60.7 to 85.8) against laboratory-confirmed influenza. Influenza-like illness was diagnosed in 132 in the vaccine group compared with 420 in the control group, resulting in a VE of 64.1% (95%CI: 56.2 to 70.6). The estimated VE against influenza B viruses was 80.5% (95%CI: 65.6 to 88.9) and 8.6% (95%CI: \u2212241 to 75.5) against influenza A viruses. In conclusion, the trivalent influenza vaccine is moderately effective, highly immunogenic, and generally safe to use in healthy male military servicemen.<\/jats:p>","DOI":"10.3390\/vaccines11091439","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:45:51Z","timestamp":1693482351000},"page":"1439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Influenza Vaccination on Rate of Influenza Virus Infection in Chinese Military Personnel, 2015\u20132016: A Cluster Randomized Trial"],"prefix":"10.3390","volume":"11","author":[{"given":"Yapin","family":"Li","sequence":"first","affiliation":[{"name":"Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxing","family":"Yu","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Ltd., No. 39, Shangdi West Road, Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Ltd., No. 39, Shangdi West Road, Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Song","sequence":"additional","affiliation":[{"name":"Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-9971","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Sinovac Life Sciences Ltd., Beijing 102601, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqi","family":"Gao","sequence":"additional","affiliation":[{"name":"Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiulan","family":"Chen","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Ltd., No. 39, Shangdi West Road, Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Huo","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Ltd., No. 39, Shangdi West Road, Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[{"name":"Sinovac Life Sciences Ltd., Beijing 102601, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huisuo","family":"Yang","sequence":"additional","affiliation":[{"name":"Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Ltd., No. 39, Shangdi West Road, Beijing 100085, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: A modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"ref_2","unstructured":"World Health Organization (2022). Vaccines against influenza: WHO position paper\u2014May 2022. Wkly. Epidemiol. Rec., 97, 185\u2013208."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/S2468-2667(19)30163-X","article-title":"Influenza-associated excess respiratory mortality in China, 2010\u201315: A population-based study","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Public Health"},{"key":"ref_4","first-page":"CD004879","article-title":"Vaccines for preventing influenza in healthy children","volume":"2","author":"Jefferson","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Demicheli, V., Jefferson, T., Di Pietrantonj, C., Ferroni, E., Thorning, S., Thomas, R.E., and Rivetti, A. (2018). Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004879.pub5"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Demicheli, V., Jefferson, T., Ferroni, E., Rivetti, A., and Di Pietrantonj, C. (2018). Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD004879.pub5"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","article-title":"Influenza","volume":"390","author":"Paules","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022-23 Influenza Season","volume":"71","author":"Grohskopf","year":"2022","journal-title":"MMWR Recomm. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3201\/eid1201.051007","article-title":"Reflections on the 1976 swine flu vaccination program","volume":"12","author":"Sencer","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/epirev\/mxj003","article-title":"Immunization to protect the US Armed Forces: Heritage, current practice, and prospects","volume":"28","author":"Grabenstein","year":"2006","journal-title":"Epidemiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/jama.2009.265","article-title":"Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel","volume":"301","author":"Wang","year":"2009","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"B36","DOI":"10.1016\/S0264-410X(02)00506-6","article-title":"Vaccination policies in the military: An insight on influenza","volume":"20","author":"Biselli","year":"2002","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1016\/S0264-410X(03)00380-3","article-title":"Vaccination programmes in the Italian military","volume":"21","author":"Biselli","year":"2003","journal-title":"Vaccine"},{"key":"ref_14","first-page":"1295","article-title":"Technical guidelines for the application of seasonal influenza vaccine in China (2014\u20132015)","volume":"35","author":"Feng","year":"2014","journal-title":"Chin. J. Epidemiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4161\/hv.26715","article-title":"Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu(R)","volume":"10","author":"Liu","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_16","first-page":"343","article-title":"Research on Safety and Immunogenicity of Trivalent Split Influenza Vaccine","volume":"11","author":"Li","year":"2006","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.4161\/hv.24832","article-title":"Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: A double-blind and randomized trial","volume":"9","author":"Luo","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.vaccine.2010.11.058","article-title":"Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans","volume":"29","author":"Wu","year":"2011","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/irv.12028","article-title":"Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: A randomized, double-blind, controlled phase I clinical trial","volume":"7","author":"Li","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1080\/21645515.2016.1194147","article-title":"Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military","volume":"12","author":"Gao","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_21","unstructured":"Chinese Center for Disease Control and Prevention (2017). Study Protocol of National Influenza Surveillance Program (2017), Chinese Center for Disease Control and Prevention. Available online: https:\/\/www.chinacdc.cn\/jkzt\/crb\/bl\/lxxgm\/jszl_2251\/201810\/t20181010_194587.html."},{"key":"ref_22","unstructured":"Office of the Ministry of Health (2011). Guidelines for the Diagnosis and Treatment of Influenza (2011 Edition), Ministry of Health, People\u2019s Republic of China."},{"key":"ref_23","unstructured":"World Health Organization (2015). Recommended Composition of Influenza Virus Vaccines for Use in the 2015\u20132016 Northern Hemisphere Influenza Season."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yu, H., Alonso, W.J., Feng, L., Tan, Y., Shu, Y., Yang, W., and Viboud, C. (2013). Characterization of regional influenza seasonality patterns in China and implications for vaccination strategies: Spatio-temporal modeling of surveillance data. PLoS Med., 10.","DOI":"10.1371\/journal.pmed.1001552"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/21645515.2015.1027470","article-title":"Technical guidelines for the application of seasonal influenza vaccine in China (2014\u20132015)","volume":"11","author":"Feng","year":"2015","journal-title":"Hum. Vaccine Immunother."},{"key":"ref_26","unstructured":"National Medical Products Administration (2023, July 20). Guidelines for Grading Standards of Adverse Events in Clinical Trials of Preventive Vaccine, Available online: https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20191231111901460.html."},{"key":"ref_27","unstructured":"Chinese National Influenza Center (2011). National Technical Guidelines for Surveillance of Influenza (2011 Version), Chinese Center for Diseases Control and Prevention. Available online: https:\/\/ivdc.chinacdc.cn\/cnic\/zyzx\/jcfa\/201605\/t20160520_129702.htm."},{"key":"ref_28","unstructured":"World Health Organization (2011). Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza."},{"key":"ref_29","unstructured":"National Medical Products Adninistration (2023, July 20). Good Clinical Practice for Drugs, Available online: https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/xzhgfxwj\/20200426162401243.html."},{"key":"ref_30","unstructured":"National Medical Products Adninistration (2023, July 20). Good Clinical Practice for Vaccines: Guideline and Principles, Available online: https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjyp\/20131031120001201.html."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1016\/j.vaccine.2011.07.128","article-title":"Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: A randomized, placebo-controlled trial","volume":"29","author":"Treanor","year":"2011","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/jramc-2018-001067","article-title":"Influenza syndromic surveillance and vaccine efficacy in the UK Armed Forces, 2017\u20132018","volume":"165","author":"Dermont","year":"2019","journal-title":"J. R. Army Med. Corps"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/cid\/ciw085","article-title":"Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults","volume":"62","author":"DiazGranados","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_34","unstructured":"Chinese National Influenza Center (2016). Influenza Activity Weekly Report, China, Chinese Center for Diseases Control and Prevention. Available online: https:\/\/ivdc.chinacdc.cn\/cnic\/zyzx\/lgzb\/."},{"key":"ref_35","unstructured":"European Committee for Medicinal Products for Human Use (2023, July 20). Note for Guidance on Harmonization of Requirements for Influenza Vaccines (CPMP\/ BWP\/214\/96), Available online: http:\/\/www.ema.europa.eu\/pdfs\/human\/bwp\/021496en.pdf."},{"key":"ref_36","unstructured":"Food and Drug Administration (2023, July 20). FDA Guidance for Industry Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines, Available online: https:\/\/www.gmp-compliance.org\/files\/guidemgr\/trifluvac.pdf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41579-021-00642-4","article-title":"Influenza lineage extinction during the COVID-19 pandemic?","volume":"19","author":"Koutsakos","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2010.250","article-title":"Effect of influenza vaccination of children on infection rates in Hutterite communities: A randomized trial","volume":"303","author":"Loeb","year":"2010","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1473-3099(10)70318-2","article-title":"New approaches to the assessment of vaccine herd protection in clinical trials","volume":"11","author":"Clemens","year":"2011","journal-title":"Lancet Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:44:16Z","timestamp":1760129056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/9\/1439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["vaccines11091439"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11091439","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}